Chest Medicine | Page 59 of 170 | Links Medicus Content Curation & Alerts in Medicine

‘Breakthrough’ infections do not mean COVID vaccines are failing.

10 Aug, 2021 | 09:54h | UTC

‘Breakthrough’ Infections Do Not Mean COVID Vaccines Are Failing – Scientific American

Commentary on Twitter

https://twitter.com/laurahelmuth/status/1422897892797337609

Systematic Review: Non-invasive ventilation used at night by people with COPD.

10 Aug, 2021 | 08:53h | UTC

Summary: Non-invasive ventilation (ventilators) used at night by people with chronic obstructive pulmonary disease (COPD) – Cochrane Library

Original review: Chronic non‐invasive ventilation for chronic obstructive pulmonary disease – Cochrane Library

RCT: Safety and immunogenicity of heterologous vs. homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine.

9 Aug, 2021 | 00:06h | UTC

Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial – The Lancet

Invited commentary: Optimising SARS-CoV-2 vaccination schedules – The Lancet

Related: Another study shows increased immune response with heterologous Oxford-AstraZeneca/mRNA vaccination (several articles on the subject)

Commentary on Twitter

Just published @TheLancet
A randomized mix and match trial of AZ and Pfizer vaccination in >800 people shows that mixing is safe and can engender at least as good, if not better, immune response https://t.co/V40Dy59Ia8 by @XinxueLiu and colleagues pic.twitter.com/tKl59LFz4i

— Eric Topol (@EricTopol) August 6, 2021

CDC study showed a reduced risk of reinfection with SARS-CoV-2 after covid-19 vaccination.

9 Aug, 2021 | 00:03h | UTC

Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, May–June 2021 – CDC Morbidity and Mortality Weekly Report

Commentaries on Twitter

This is non randomized. The two biases are:

1. Behavior among those who got vaccinated likely different than those who don't

2. Likely those who didn't tested more aggressively

I would not cite this as many are doinghttps://t.co/rSkBC37uq0

— Vinay Prasad MD MPH (@VPrasadMDMPH) August 7, 2021

Study shows that full #COVIDVaccination ⬇️ likelihood of being re-infected with #COVID19 compared to those who were previously had COVID but were not vaccinated (risk ⬆️ 2.3 fold)#GetVaccinated even if you have had COVID previouslyhttps://t.co/3dF3XPxwYp

@fascinatorfun pic.twitter.com/ip6zTvNN86

— Prof Kamlesh Khunti (@kamleshkhunti) August 7, 2021

M-A: SARS-CoV-2 Setting-specific transmission rates – “Households showed the highest transmission rates, with a pooled secondary attack rates of 21.1%”.

8 Aug, 2021 | 23:57h | UTC

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Setting-specific Transmission Rates: A Systematic Review and Meta-analysis – Clinical Infectious Diseases

Commentary on Twitter

SARS-CoV-2 setting-specific transmission rates: a systematic review and meta-analysis

Households highest transmission rates, pooled SAR~21.1%. Contacts at social events~5.9%. Workplaces~1.9%. Age gradient for transmission potential in h/hold context. https://t.co/m27kkDrTgy

— Andrew Lee is heading to @andrewleedr.bsky.social (@andrewleedr) March 10, 2021

COVID vaccine boosters: the most important questions.

8 Aug, 2021 | 23:52h | UTC

COVID vaccine boosters: the most important questions – Nature

Commentary on Twitter

I agree with @nataliexdean: “We just don’t have clear evidence of enough of a loss of efficacy to change our focus or distract from the main goal, which is trying to get as many people first doses” as possible." https://t.co/FEKB4vg0Dz

— Sanghyuk Shin (@sanghyuk_shin) August 6, 2021

More data showing one dose of Pfizer vaccine may be enough for individuals who’ve had COVID.

8 Aug, 2021 | 23:50h | UTC

Commentary: One Dose of Pfizer Vaccine May Be Enough for Folks Who’ve Had COVID – HealthDay

Original Study: SARS-CoV-2 Antibody Responses in Infection-Naive or Previously Infected Individuals After 1 and 2 Doses of the BNT162b2 Vaccine – JAMA Network Open

Perspective | Is one vaccine dose enough if you’ve had COVID? What the science says.

Another study shows a single dose of mRNA vaccine may be enough for patients with previous Covid-19

Spain to give just one vaccine dose to under 55-year olds who had COVID-19

Perspective: Is one vaccine dose enough after COVID-19 infection?

France’s health authority recommends single vaccine shot for people who have had COVID-19

Covid-19: People who have had infection might only need one dose of mRNA vaccine

Commentary on Twitter

SARS-CoV-2 Antibody Responses After 1 and 2 Doses of the BNT162b2 Vaccine https://t.co/ARMdH8Yboo via @JAMANetworkOpen part of @JAMANetwork Small study but one that confirms the policy of many European countries in which one dose of vaccine is sufficient after having COVID.

— Carlos del Rio (@CarlosdelRio7) August 7, 2021

Case report: Systemic capillary leak syndrome after ChAdOx1 nCOV-19 (Oxford–AstraZeneca) vaccination.

8 Aug, 2021 | 23:49h | UTC

Systemic capillary leak syndrome afer ChAdOx1 nCOV-19 (Oxford–AstraZeneca) vaccination – Canadian Medical Association Journal

Pediatric asthma: The REGAP consensus.

8 Aug, 2021 | 23:45h | UTC

Pediatric asthma: The REGAP consensus – Anales de Pediatría

Perspective: Does Treating Sleep Apnea With CPAP Improve Cardiovascular Outcomes or Lower Risk of Atrial Fibrillation? – “Despite numerous flawed observational studies suggesting an association between sleep apnea and cardiovascular outcomes including atrial fibrillation the gold standard, high-quality RCT data do not clearly show that treatment of sleep apnea with CPAP improves cardiovascular outcomes”.

8 Aug, 2021 | 23:31h | UTC

Does Treating Sleep Apnea With CPAP Improve Cardiovascular Outcomes or Lower Risk of Atrial Fibrillation? – The Skeptical Cardiologist

AHA Scientific Statement: Obstructive Sleep Apnea and Cardiovascular Disease.

Non-sleepy Obstructive Sleep Apnea: To Treat or Not to Treat?

Pro/Con Debate: Should Asymptomatic Patients with Moderate-to-severe OSA be Treated?

Obstructive Sleep Apnea in Cardiovascular Disease: A Review of the Literature and Proposed Multidisciplinary Clinical Management Strategy

Positive airway pressure doesn’t reduce cardiovascular events and death in adults with sleep apnea

[Preprint] RCT: non-invasive respiratory strategies in acute respiratory failure in patients with COVID-19 – CPAP reduced the composite outcome of intubation or death within 30 days; high-flow nasal oxygenation was not associated with better outcomes.

6 Aug, 2021 | 10:18h | UTC

An adaptive randomized controlled trial of non-invasive respiratory strategies in acute respiratory failure patients with COVID-19 – medRxiv

Commentary: Covid: Pressured oxygen reduces ventilator need – BBC

Commentary on Twitter (thread – click for more)

RECOVERY-RS results out, and confirm what most of us have been doing:

CPAP reduces intubation/mortality by 28% compared with no CPAP/HFNO (composite outcome, mostly intubation)
Nasal high flow not so successful

1/https://t.co/bcB2sTdAsu pic.twitter.com/fvT8IbyxUr

— 𝚃𝚘𝚖 𝙻𝚊𝚠𝚝𝚘𝚗 💙 (@LawtonTri) August 5, 2021

Systematic Review: “Remdesivir probably has little or no effect on all‐cause mortality at up to 28 days in hospitalized adults with SARS‐CoV‐2 infection. We are uncertain about the effects of remdesivir on clinical improvement and worsening”.

6 Aug, 2021 | 10:15h | UTC

Remdesivir for the treatment of COVID‐19 – Cochrane Library

Summary: Remdesivir for the treatment of COVID-19 – Cochrane Library

Commentary on Twitter (thread – click for more)

JUST PUBLISHED – Is #remdesivir an effective treatment for #COVID19? https://t.co/ntgfDQjMqs This @CochraneHaem systematic review looked at this antiviral medicine to see if it's an effective treatment for people in hospital w #COVID & if it causes unwanted effects. 1/5 pic.twitter.com/UtIW83uTtn

— The Cochrane Library (@CochraneLibrary) August 5, 2021

Dexamethasone and tocilizumab treatment considerably reduces the value of C-reactive protein and procalcitonin to detect secondary bacterial infections in COVID-19 patients.

6 Aug, 2021 | 10:13h | UTC

Dexamethasone and tocilizumab treatment considerably reduces the value of C-reactive protein and procalcitonin to detect secondary bacterial infections in COVID-19 patients – Critical Care

Clinical Picture: Mucormycosis after COVID-19 in a patient with diabetes.

6 Aug, 2021 | 10:09h | UTC

Mucormycosis after COVID-19 in a patient with diabetes – The Lancet

COVID-19 and mucormycosis superinfection: the perfect storm.

ECMM/ISHAM recommendations for clinical management of COVID -19 associated mucormycosis in low- and middle-income countries.

The “Black Fungus” in India: The Emerging Syndemic of COVID-19–Associated Mucormycosis – careful use of antibiotics and corticosteroids and closely monitoring blood glucose levels are some of the strategies suggested by the authors.

Multicenter Epidemiologic Study of Coronavirus Disease–Associated Mucormycosis, India – Uncontrolled diabetes mellitus was the most common underlying disease; improper glucocorticoid use was independently associated with the disease.

Opinion | “Doctors have been blamed for the rise in black fungus in India, but the COVID treatment guidelines could be contributing” – improper use of antibiotics and higher than usual doses of corticosteroids may be contributing to the emergence of mucormycosis and other fungal co-infections.

What is mucormycosis, the fungal infection affecting COVID patients in India?

[Preprint] The Emergence of COVID-19 Associated Mucormycosis: Analysis of Cases From 18 Countries.

Mucormycosis: The ‘black fungus’ maiming Covid patients in India

Global Guideline for the Diagnosis and Management of Mucormycosis

M-A: Chest radiograph findings in COVID-19.

6 Aug, 2021 | 10:03h | UTC

Systematic review and meta-analysis of chest radiograph (CXR) findings in COVID-19 – Clinical Imaging

Fibrotic interstitial lung abnormalities at 1-year follow-up CT after severe COVID-19.

6 Aug, 2021 | 10:01h | UTC

Fibrotic Interstitial Lung Abnormalities at 1-year Follow-up CT after Severe COVID-19 – Radiology

Commentary on Twitter

Data on 1 year outcomes for patients with post-COVID lung fibrosis. Small study, very little clinical information, including on treatment, and I object to the use of the term ILA, but overall not suggestive of progressive fibrotic lung disease. Thoughts?https://t.co/Kdt1pmTREl pic.twitter.com/mu1Jd2G6sd

— Anna Podolanczuk (@AnnaPodolanczuk) August 4, 2021

International, multicenter observational study: Outcomes with percutaneous dilatational tracheotomy in high-risk ICU patients.

6 Aug, 2021 | 08:59h | UTC

Percutaneous dilatational tracheotomy in high-risk ICU patients – Annals of Intensive Care

SARS-CoV-2 Variants in Patients with Immunosuppression.

5 Aug, 2021 | 09:02h | UTC

SARS-CoV-2 Variants in Patients with Immunosuppression – New England Journal of Medicine

Commentary on Twitter

In the pandemic, immunocompromised people (~3% of Americans) are not getting adequate recognition for the potential of in-host evolution of the virus (highlighted studies) and the need for far better approaches to protect them https://t.co/XDT1VxC9ZK @NEJM pic.twitter.com/ciw1WD9EzC

— Eric Topol (@EricTopol) August 4, 2021

RCT: In noncritically ill patients hospitalized with Covid-19, therapeutic-dose anticoagulation with heparin increased the probability of survival to hospital discharge compared with usual-care thromboprophylaxis.

5 Aug, 2021 | 09:07h | UTC

Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19 – New England Journal of Medicine

Editorial: Surviving Covid-19 with Heparin?

Commentaries:

Full-dose blood thinners reduce the need for organ support in moderately ill COVID-19 patients, but not in critically ill patients – National Institutes of Health

Therapeutic-Dose Heparin in COVID-19: Who Benefits, Who Doesn’t – TCTMD

Canadian-Led International Study: Full-Dose Blood Thinners Benefit Moderately Ill COVID-19 Patients – University of Manitoba

Commentary on Twitter

In noncritically ill patients with #COVID19, anticoagulation increased the probability of survival to hospital discharge without organ support. https://t.co/3JzKdmL3SB #IDTwitter pic.twitter.com/iDjSelp2HL

— NEJM (@NEJM) August 4, 2021

RCT: In critically ill patients with Covid-19, therapeutic anticoagulation with heparin did not result in improved outcomes compared to usual-care pharmacologic thromboprophylaxis.

5 Aug, 2021 | 09:04h | UTC

Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19 – New England Journal of Medicine

Editorial: Surviving Covid-19 with Heparin?

Commentaries:

Full-dose blood thinners reduce the need for organ support in moderately ill COVID-19 patients, but not in critically ill patients – National Institutes of Health

Therapeutic-Dose Heparin in COVID-19: Who Benefits, Who Doesn’t – TCTMD

Commentary on Twitter

Anticoagulation did not improve hospital survival in critically Ill patients with #COVID19. https://t.co/E8RXE01jbF pic.twitter.com/9idGxgbUas

— NEJM (@NEJM) August 4, 2021

RCT: Subcutaneous REGEN-COV antibody combination prevented symptomatic Covid-19 infection in previously uninfected household contacts of infected persons.

5 Aug, 2021 | 09:01h | UTC

Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19 – New England Journal of Medicine

RCT: Bamlanivimab plus Etesevimab reduce mortality and hospitalization in ambulatory patients with early Covid-19 (within 3 days of a positive test) who are at risk for clinical deterioration (i.e., older people, obese, diabetics, immunocompromised, with CV disease).

[Preprint] RECOVERY trial finds Regeneron’s monoclonal antibody combination reduces deaths for hospitalized COVID-19 patients who have not mounted their own immune response.

Commentary on Twitter

Subcutaneous REGEN-COV prevented symptomatic #COVID19 and asymptomatic #SARSCoV2 infection in previously uninfected household contacts. https://t.co/rRNFTjS9hX pic.twitter.com/B7qXeyWKUb

— NEJM (@NEJM) August 4, 2021

Review: Lung transplantation for interstitial lung disease.

5 Aug, 2021 | 08:32h | UTC

Lung transplantation for interstitial lung disease – European Respiratory Review

Illness duration and symptom profile in symptomatic school-aged children tested for SARS-CoV-2 – “Only 25 (1.8%) of 1379 children experienced symptoms for at least 56 days.”

4 Aug, 2021 | 10:06h | UTC

Illness duration and symptom profile in symptomatic UK school-aged children tested for SARS-CoV-2 – The Lancet Child & Adolescent Health

Invited commentary: Citizen science and biomedical research (free registration required)

Commentaries:

Expert reaction to study looking at long-lasting symptoms from COVID-19 in children – Science Media Centre

Long Covid uncommon in children, analysis finds – King’s College London

Study finds long-term Covid symptoms rare in school-age children – The Guardian

Most children with Covid-19 recover within a week, but a small percentage have long-term symptoms, a study says. – The New York Times

Long-term Symptoms After SARS-CoV-2 Infection in Children and Adolescents – “This study found a low prevalence of symptoms compatible with long COVID in a randomly selected cohort of children assessed 6 months after serologic testing”.

Cohort study: Risk factors for long covid in previously hospitalized children.

Study shows low incidence of post-acute COVID-19 symptoms (“Long Covid”) in children after mild disease

Commentary on Twitter

New @LancetChildAdol is a very reassuring prospective study of >250,000 children, >1700 with + covid test, age 5-17, that shows the risk for chronic Covid symptoms is quite low; 4.4% beyond 4 weekshttps://t.co/XVFs0UtHWC pic.twitter.com/XBVH5wmFve

— Eric Topol (@EricTopol) August 3, 2021